Drugs / Tetraprizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04313660 | Apr 2020 → Feb 2021 | non-small cell lung carcinoma | Xiaorong Dong | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetraprizumab | “Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.” NCT04313660 ↗ |
| Route | Intravenous | “Tetraprizumab injection, 240mg, IV, once every three weeks” NCT04313660 ↗ |